Skip to navigation Skip to content

Clinical Trial: Siponimod in advancing forms of relapsing MS

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To reduce disease activity
Number of Subjects: 5
Medication: siponimod
Location: Colorado
Institutions: Mountain View Clinical Research Contact Information
Brian Johnson, ext. 703
720-941-9363
brian@mtnresearch.com

Funding:

Novartis

Description

Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis. You, or someone you care for, may be able to take part if you/they:
• are a man or woman, 18–65 years of age
• have advancing RMS (where symptoms are getting worse over time)
•  have been treated with an MS therapy (beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide) for at least 3 months.

Participants will be compensated for completing study visits.
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.